Drug
Imatinib Mesylate (Gleevec)
Imatinib Mesylate (Gleevec) is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
20%(1 trials)
Phase Distribution
Ph phase_2
2
40%
Ph not_applicable
1
20%
Ph phase_1
2
40%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
2(40.0%)
N/ANon-phased studies
1(20.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(5)
Detailed Status
Completed5
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (40.0%)
Phase 22 (40.0%)
N/A1 (20.0%)
Trials by Status
completed5100%
Recent Activity
0 active trials
Showing 5 of 5
completednot_applicable
Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
NCT00038675
completedphase_1
Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia
NCT00047502
completedphase_1
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP
NCT00088231
completedphase_2
Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST
NCT00500188
completedphase_2
Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study
NCT00131274
Clinical Trials (5)
Showing 5 of 5 trials
NCT00038675Not Applicable
Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
NCT00047502Phase 1
Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia
NCT00088231Phase 1
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP
NCT00500188Phase 2
Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST
NCT00131274Phase 2
Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5